ILC2 Cell Therapy Suppresses Microglial Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for neurodegenerative diseases associated with microglial activation and blood-brain barrier disruption are ineffective due to off-target effects and unclear long-term outcomes, highlighting a need for more reliable methods to suppress microglial activation and stabilize the blood-brain barrier.
Innovation Solution
Administering type II innate lymphoid cells (ILC2s), specifically increasing their number and activity, either through direct administration of activated ILC2s or agents that enhance their production of IL-10 and Timp1, to suppress microglial activation and stabilize the blood-brain barrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to suppress microglial activation, then microglial activation is reduced, but off-target effects occur and long-term outcomes are unclear
Solution Approach 1:
The patent introduces type II innate lymphoid cells (ILC2s) as intermediary cells that mediate the suppression of microglial activation. Instead of directly targeting microglia with compounds that cause off-target effects, ILC2s are administered to produce anti-inflammatory cytokines (IL-10, IL-13) that indirectly suppress microglial activation through physiological pathways, thereby reducing off-target effects while maintaining therapeutic effectiveness.
Solution Approach 2:
The patent utilizes the body's own immune system components (ILC2s) to treat the disease. ILC2s are endogenous cells that can be expanded and administered back to the patient, where they naturally produce anti-inflammatory cytokines to suppress microglial activation. This self-service approach avoids the need for external compounds with unknown long-term effects, improving reliability and reducing harmful off-target effects.
2Object-affected harmful factors
If microglial activation is suppressed, then neuroinflammation is reduced, but blood-brain barrier disruption occurs
Solution Approach 1:
The patent changes the immunological parameters by administering ILC2s that produce specific cytokine profiles (IL-10, IL-13) to shift the immune response from pro-inflammatory to anti-inflammatory. This parameter change suppresses microglial activation and neuroinflammation while simultaneously promoting blood-brain barrier stability through the same anti-inflammatory mechanisms, thereby resolving the contradiction between reducing neuroinflammation and maintaining barrier integrity.
Data Source
AI summary
Compositions and methods of using ILC2 to reduce microglial activation or to reduce blood-brain barrier (BBB) permeability are described. Also described are methods and compositions that use an agent that increases the number of activated ILC2 to reduce microglial activation or BBB permeability.